Suzhou Synovision Completes RMB 700 Million Series E Financing to Accelerate Innovative Drug Development and Commercialization

At the dawn of the Year of the Dragon, all things flourish.Evopoint Biosciences Co.,Ltd.(hereinafter referred to as “Evopoint Biosciences” or the “Company”)Successfully completed a Series E financing round of RMB 700 million.This round of financing was co-led by Tencent Investment and Guoxin Investment, with participation from multiple renowned institutions including Jinan Industrial Development, Huakong Investment, Yuekai Capital, Chenhai Capital, Pudong Venture Capital, and Zhuopu Capital. Existing shareholder Loyal Valley Capital continued its support, while Start Point Advisors served as the exclusive financial advisor for this round.

The funds raised in this round will be primarily used to advance domestic and international clinical trials across the Company’s multiple pipelines, enhance its three proprietary technology platforms for targeted therapy, anti-infectives, and PROTACs, accelerate the operation of manufacturing facilities and the build-out of commercialization teams, and expedite product launches to benefit a broad patient population.

Evopoint Biosciences, founded in 2017, is a platform-based innovative pharmaceutical company that combines scientific research strength with commercialization capabilities. Always committed to advancing human health, the company is dedicated to providing high-quality solutions for major unmet clinical needs worldwide. Leveraging its independently developed technology platforms, Evopoint Biosciences has established a globally leading pipeline of innovative drugs, including BLI inhibitors, EZH2 inhibitors, hURAT1 inhibitors, and next-generation antibody-drug conjugates (ADCs), covering therapeutic areas such as oncology, multidrug-resistant bacterial infections, and metabolic disorders. Currently, the company has nine products in various stages of clinical development both domestically and internationally, two of which have entered Phase III clinical trials.

Among these, XNW4107 is a next-generation broad-spectrum anti-drug-resistant β-lactamase inhibitor independently developed by Evopoint Biosciences. It demonstrates potent antibacterial efficacy against carbapenem-resistant bacterial infections that have been increasing year by year in recent years, such as carbapenem-resistant Acinetobacter baumannii (CRAB), carbapenem-resistant Pseudomonas aeruginosa (CRPA), and carbapenem-resistant Enterobacterales (CRE). The drug is currently undergoing global multicenter pivotal Phase III clinical trials.

XNW3009 is a next-generation uric acid-lowering agent that has currently entered Phase III clinical trials. Two previously completed randomized, double-blind, controlled trials, which used benzbromarone (the most prescribed drug in the Chinese market) and febuxostat (the highest-grossing drug in the Chinese market) as respective controls, demonstrated that XNW3009’s uric acid-lowering efficacy was significantly superior to that of the control groups.

In the field of oncology, the next-generation EZH2 inhibitor XNW5004 has demonstrated excellent anti-tumor efficacy in indications such as hematologic malignancies and prostate cancer. It is currently in Phase II clinical trials and has entered into a collaboration with MSD to conduct combination therapy clinical trials with Keytruda. The next-generation antibody-drug conjugates (ADCs) XNW27 and XNW28 are in Phase I clinical trials, having already shown the potential for significantly superior efficacy and a wider therapeutic window compared to competing products targeting the same antigens.

Leveraging its robust product portfolio and strong out-licensing capabilities, Evopoint Biosciences has entered into multiple out-licensing agreements with renowned domestic and international companies, with a total value amounting to billions of US dollars. It is currently one of the Chinese biopharmaceutical companies with the highest number of license-out deals.

Since its inception, the company has gained significant recognition from investors, securing investments from top-tier domestic and international institutions including Loyal Valley Capital, GIC, Tencent Investment, Haisong Capital, and CICC Capital. It has also received strong support from state-backed entities such as Shanghai Guoxin Investment And Development Co.,Ltd., Jinan Industrial Development Fund Management Co., Ltd., Lianxun Capital Investment Co., Ltd., Shanghai Pudong Venture Investment Co., Ltd., National Development Venture Capital, Suzhou Zhuopu Investment Fund Management Co., Ltd, and ABC International. To date, the company has raised over RMB 2 billion in cumulative financing.

Soaring Across the Four Seas, Bathed in Divine Essence; Evopoint Pursues Truth and Nurtures Excellence. Evopoint Biosciences will continue to unite hearts and minds, remain steadfast in confidence, sustain its passion and momentum, advance hand in hand, and jointly create a brighter future.

The Series E investor stated: “We are delighted to participate in Evopoint Biosciences’ Series E financing round. Evopoint is an innovative pharmaceutical company focused on addressing significant unmet clinical needs. Since the last funding round, the company has demonstrated impressive execution capabilities, with multiple products approaching the stage of commercial validation. It has successfully transitioned from a ‘product-centric’ to a ‘platform-centric’ enterprise, establishing several leading technology platforms. Leveraging its efficient R&D system and exceptional research capabilities, the company has actively expanded overseas, completing multiple out-licensing deals for international rights to its pipeline assets. We remain firmly confident in Evopoint’s founding team and product pipeline, and we hope this round of financing will help accelerate the market launch of its products to benefit a broad patient population.”

Shanghai Guoxin Investment And Development Co.,Ltd. was established in 2000 with a registered capital of RMB 4 billion and is a wholly-owned subsidiary of Shanghai State-owned Assets Operation Co., Ltd. With years of experience in equity investment, Guoxin Investment has demonstrated strong capabilities in project screening, investment, and management. It has successfully invested in numerous renowned domestic biopharmaceutical and medical device enterprises, including Tigermed, Aier Eye Hospital Group, Dongcheng Pharmaceutical, United Imaging Healthcare, and Lepu Medical. Adhering to its business philosophy of “discovering value, creating value, and growing together with outstanding enterprises,” Guoxin Investment will continue to play a significant role in implementing the strategic functions of Shanghai International Group, empowering the real economy through financial capital and supporting the construction of Shanghai as a global science and technology innovation center.

Jinan Industrial Development Investment Group Co., Ltd. was established in 2016. It is a state-controlled group company approved by the Jinan Municipal People's Government, integrating businesses such as industrial investment, park development, and industrial operations. Under the leadership of the Municipal Party Committee and the Municipal People's Government, the Group adheres to its mission of “Revitalizing the City through Industry and Serving the Country through Development.” Focusing on strategic emerging industries such as next-generation information technology, new energy, biopharmaceuticals, and high-end equipment manufacturing, it has established three major fund platforms: the Industrial Development Fund, the Economic Development Fund, and the Science and Technology Innovation Investment Fund. Additionally, it has set up more than 50 parent and subsidiary funds, with a total committed capital of nearly RMB 50 billion across participating funds, and has invested in approximately 200 projects. The Group has developed and operated over 10 million square meters of industrial parks, attracted more than 1,500 enterprises, and created over 15,000 jobs, thereby providing park carriers for the cultivation of industrial clusters.

Loyal Valley Capital has always adhered to the investment values of “long-termism, focus, and altruism,” striving to build China’s premier investment research and post-investment management teams. Covering three major sectors—new technology, new healthcare, and new consumption—the firm leverages in-depth industry research and proactive post-investment value creation to partner with outstanding entrepreneurs. Together, they aim to build great enterprises that represent the future growth direction of China’s economy and create value for society. Since its establishment in 2015, Loyal Valley Capital has invested in over 100 leading companies that exemplify the future trajectory of China’s economic development, including SUPCON Technology, Unisoc, CALB, Avary Holding, Rigol Technologies, O-Net Communications, Bayi Space, Junshi Biosciences, InnoCare Pharma, Akeso Biopharma, RemeGen, CARsgen Therapeutics, Obio Technology, Allist, Bilibili, ByteDance, POP MART, and NetEase Cloud Music.

Huakong Investment was established in 2007. It manages over 20 subsidiary funds, including venture capital (VC), private equity (PE), industrial funds, merger and acquisition (M&A) funds, overseas funds, and general aviation funds, covering various investment stages and specialized sectors. With assets under management exceeding RMB 10 billion, the firm is committed to becoming China’s leading private equity investment institution. The funds focus on investing in market leaders within niche industries, with particular emphasis on high-growth sectors such as advanced manufacturing and high-end equipment, next-generation information technology, carbon neutrality, and biotechnology.

Lianxun Capital, established in 2016, has launched 12 actively managed funds since its inception, with assets under management nearing RMB 6 billion. Its investment portfolio includes projects such as Avatr, Kyland Technology, Tofflon, SVOLT, Guangzhou Lijing, Hongji Chuangneng, and Tongyu Auto. Since returning to the Huangpu District and Guangzhou Development District in 2021, the firm has leveraged regional industrial resource advantages to successfully invest in more than 10 projects, empowering the growth of technology-driven enterprises with financial capital.

Shanghai Pudong Innovation Investment Development (Group) Co., Ltd., with the State-owned Assets Supervision and Administration Commission of Pudong New Area fulfilling its investor responsibilities, has a registered capital of RMB 10 billion. Centered on “cultivating technological innovation and promoting the development of emerging industries,” the company achieves synergistic integration across six core business areas: angel investment, industrial investment, strategic investment, fund investment, post-investment management, and industrial research, thereby building an investment system that covers the entire lifecycle of sci-tech innovation enterprises. By aligning the capital chain with the innovation chain, it guides the aggregation of more capital, projects, talent, and technology in Pudong to empower sci-tech innovation enterprises, ensuring that “promising ideas never lack funding, and promising enterprises never lack capital.” Shanghai Pudong Venture Capital focuses on investing early and in small-scale ventures by targeting industry trends and future industrial breakthrough points, while also investing in large and strong entities by focusing on strategic leading enterprises, high-level chain leaders, and major functional platforms. This approach injects new vitality into industrial development, creates new value, and promotes a regional landscape where “small enterprises are widespread and large enterprises stand tall and firm.”

Suzhou Zhuopu Investment Fund Management Co., Ltd., established in 2018 as a wholly-owned subsidiary of Suzhou Asset Management Co., Ltd., has long focused on fields such as next-generation information technology, aerospace, semiconductors, biopharmaceuticals, and artificial intelligence, with assets under management exceeding RMB 2 billion. Zhuopu Capital actively manages several direct investment funds, including Zhuopu No. 1 Fund, Gusu Talent Phase II Fund, Zhangjiagang Talent No. 1 Fund, Zhuopu Yongying Fund, and Zhuoyun Qihang Fund, with a key focus on Suzhou’s four pillar industries: electronic information, high-end equipment, advanced materials, and new energy.

Start Point Advisors is committed to building a premier next-generation investment bank in China’s healthcare and life sciences sector. Founded in 2020, the firm is headquartered in Beijing and Shanghai, with a team composed of professionals from renowned industry institutions who possess extensive practical experience. Over the past four years, Start Point Advisors has covered all mainstream sub-sectors and financing stages within the industry. It is also one of the few firms in China with proven track records across various transaction types, including private equity financing, mergers and acquisitions (M&A), business development (BD), and exit strategies via share transfers.